Branched fatty acid esters of hydroxy fatty acids (FAHFAs) protect against colitis by regulating gut innate and adaptive immune responses

Journal of Biological Chemistry

Volumn 291, Issue 42, 2016, Pages 22207-22217

  Lee, Jennifer ^a   Moraes Vieira, Pedro M ^a,e   Castoldi, Angela ^a,f   Aryal, Pratik ^a   Yee, Eric U ^b   Vickers, Christopher ^c   Parnas, Oren ^d,g   Donaldson, Cynthia J ^c   Saghatelian, Alan ^c   Kahn, Barbara B ^a  

^a Division of Endocrinology Diabetes and Hypertension   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e UNIVERSITY OF CAMPINAS   (Brazil)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

^g HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROLIFERATION; CELLS; CHEMICAL ACTIVATION; CYTOLOGY; DISEASES; ESTERS; FATTY ACIDS; GENE EXPRESSION; IMMUNE SYSTEM; MAMMALS; PALMITIC ACID; SODIUM SULFATE; VEHICLES;

ADAPTIVE IMMUNE RESPONSE; ADAPTIVE IMMUNE SYSTEMS; ANTI-INFLAMMATORY EFFECTS; ANTIGEN PRESENTATION; CHEMOKINE EXPRESSION; CHRONIC INFLAMMATORY DISEASE; DEXTRAN SULFATE SODIUM; HYDROXY STEARIC ACID;

T-CELLS;

5 PALMITIC ACID HYDROXY STEARIC ACID; 9 PALMITIC ACID HYDROXY STEARIC ACID; BRANCHED FATTY ACID ESTERS OF HYDROXY FATTY ACID; FATTY ACID ESTER; G PROTEIN COUPLED RECEPTOR 120; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17; LIPOPOLYSACCHARIDE; PROTECTIVE AGENT; UNCLASSIFIED DRUG; DEXTRAN SULFATE; FATTY ACID; G PROTEIN COUPLED RECEPTOR; O3FAR1 PROTEIN, MOUSE;

ADAPTIVE IMMUNITY; ANALYTICAL PARAMETERS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BONE MARROW DERIVED DENDRITIC CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COCULTURE; COLITIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; EX VIVO STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOREGULATION; IN VIVO STUDY; INNATE IMMUNITY; INTESTINE CRYPT; MALE; MOLECULAR DYNAMICS; MONOTHERAPY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PANETH CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM HEMORRHAGE; SPLEEN CELL; STOOL CONSISTENCY; T LYMPHOCYTE ACTIVATION; WILD TYPE; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; IMMUNOLOGY; MUCOSAL IMMUNITY; PATHOLOGY; TH1 CELL;

ADAPTIVE IMMUNITY; ANIMALS; COLITIS; DEXTRAN SULFATE; FATTY ACIDS; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; MALE; MICE; PANETH CELLS; RECEPTORS, G-PROTEIN-COUPLED; TH1 CELLS;

EID: 84991744596     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.703835     Document Type: Article

References (50)

1. Clardy, J., and Walsh, C. (2004) Lessons from natural molecules. Nature 432, 829-837
2. Funk, C. D. (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294, 1871-1875
3. Corey, E. J., Schaaf, T. K., Huber, W., Koelliker, U., and Weinshenker, N. M. (1970) Total synthesis of prostaglandins F2-α and E2 as the naturally occurring forms. J. Am. Chem. Soc. 92, 397-398
4. Higenbottam, T., Butt, A. Y., McMahon, A., Westerbeck, R., and Sharples, L. (1998) Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 80, 151-155
5. Lindén, C., and Alm, A. (1999) Prostaglandin analogues in the treatment of glaucoma. Drugs Aging 14, 387-398
6. Moncada, S., and Vane, J. R. (1978) Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol. Rev. 30, 293-331
7. Gonzalez-Cabrera, P. J., Cahalan, S. M., Nguyen, N., Sarkisyan, G., Leaf, N. B., Cameron, M. D., Kago, T., and Rosen, H. (2012) S1P(1) receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis. Mol. Pharmacol. 81, 166-174
8. Yore, M. M., Syed, I., Moraes-Vieira, P. M., Zhang, T., Herman, M. A., Homan, E. A., Patel, R. T., Lee, J., Chen, S., Peroni, O. D., Dhaneshwar, A. S., Hammarstedt, A., Smith, U., McGraw, T. E., Saghatelian, A., and Kahn, B. B. (2014) Discovery of a class of endogenous mammalian lipids with anti-diabetic and anti-inflammatory effects. Cell 159, 318-332
9. Kitahora, T., Utsunomiya, T., and Yokota, A. (1995) Epidemiological study of ulcerative colitis in Japan: incidence and familial occurrence: the Epidemiology Group of the Research Committee of Inflammatory Bowel Disease in Japan. J. Gastroenterol. 30, 5-8
10. Lakatos, L., Mester, G., Erdelyi, Z., Balogh, M., Szipocs, I., Kamaras, G., and Lakatos, P. L. (2004) Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977-2001. World J. Gastroenterol. 10, 404-409
11. Molodecky, N. A., Soon, I. S., Rabi, D. M., Ghali, W. A., Ferris, M., Chernoff, G., Benchimol, E. I., Panaccione, R., Ghosh, S., Barkema, H. W., and Kaplan, G. G. (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142, 46-54.e42; quiz e30
12. Feuerstein, J. D., and Cheifetz, A. S. (2014) Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clinic Proc. 89, 1553-1563
13. Danese, S., Sans, M., and Fiocchi, C. (2004) Inflammatory bowel disease: the role of environmental factors. Autoimmun. Rev. 3, 394-400
14. Dignass, A. U., Baumgart, D. C., and Sturm, A. (2004) Review article: the aetiopathogenesis of inflammatory bowel disease: immunology and repair mechanisms. Aliment. Pharmacol. Ther. 20, 9-17
15. Gersemann, M., Wehkamp, J., and Stange, E. F. (2012) Innate immune dysfunction in inflammatory bowel disease. J. Internal Med. 271, 421-428
16. Pastorelli, L., De Salvo, C., Mercado, J. R., Vecchi, M., and Pizarro, T. T. (2013) Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front. Immunol. 4, 280
17. Eaden, J. A., Abrams, K. R., and Mayberry, J. F. (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48, 526-535
18. Curdia and Goncalves, T. (2015) Impact of the age of diagnosis on the natural history of ulcerative colitis. Rev. Esp. Enferm. Dig. 107, 614-621
19. Damas, O. M., Deshpande, A. R., Avalos, D. J., and Abreu, M. T. (2015) Treating inflammatory bowel disease in pregnancy: the issues we face today. J. Crohns Colitis 9, 928-936
20. Horst, S., and Kane, S. (2014) The use of biologic agents in pregnancy and breastfeeding. Gastroenterol. Clin. North Am. 43, 495-508
21. Castoldi, A., Favero de Aguiar, C., Moraes-Vieira, P. M., and Olsen Saraiva Câmara, N. (2015) They must hold tight: junction proteins, microbiota and immunity in intestinal mucosa. Curr. Protein Pept. Sci. 16, 655-671
22. Hirasawa, A., Tsumaya, K., Awaji, T., Katsuma, S., Adachi, T., Yamada, M., Sugimoto, Y., Miyazaki, S., and Tsujimoto, G. (2005) Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat. Med. 11, 90-94
23. Briscoe, C. P., Tadayyon, M., Andrews, J. L., Benson, W. G., Chambers, J. K., Eilert, M. M., Ellis, C., Elshourbagy, N. A., Goetz, A. S., Minnick, D. T., Murdock, P. R., Sauls, H. R., Jr., Shabon, U., Spinage, L. D., Strum, J. C., et al. (2003) The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J. Biol. Chem. 278, 11303-11311
24. Oh, D. Y., Talukdar, S., Bae, E. J., Imamura, T., Morinaga, H., Fan, W., Li, P., Lu, W. J., Watkins, S. M., and Olefsky, J. M. (2010) GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142, 687-698
25. Turner, D., Walsh, C. M., Steinhart, A. H., and Griffiths, A. M. (2007) Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin. Gastroenterol. Hepatol. 5, 103-110
26. Bewtra, M., Kilambi, V., Fairchild, A. O., Siegel, C. A., Lewis, J. D., and Johnson, F. R. (2014) Patient preferences for surgical versus medical therapy for ulcerative colitis. Inflamm. Bowel Dis. 20, 103-114
27. Cho, J. Y., Chi, S. G., and Chun, H. S. (2011) Oral administration of docosahexaenoic acid attenuates colitis induced by dextran sulfate sodium in mice. Mol. Nutr. Food Res. 55, 239-246
28. Ishida, T., Yoshida, M., Arita, M., Nishitani, Y., Nishiumi, S., Masuda, A., Mizuno, S., Takagawa, T., Morita, Y., Kutsumi, H., Inokuchi, H., Serhan, C. N., Blumberg, R. S., and Azuma, T. (2010) Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. Inflamm. Bowel Dis. 16, 87-95
29. Chen, C., Shah, Y. M., Morimura, K., Krausz, K. W., Miyazaki, M., Richardson, T. A., Morgan, E. T., Ntambi, J. M., Idle, J. R., and Gonzalez, F. J. (2008) Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis. Cell Metab. 7, 135-147
30. Loeschke, K., Ueberschaer, B., Pietsch, A., Gruber, E., Ewe, K., Wiebecke, B., Heldwein, W., and Lorenz, R. (1996) n-3 fatty acids only delay early relapse of ulcerative colitis in remission. Digest. Dis. Sci. 41, 2087-2094
31. Almallah, Y. Z., Richardson, S., O'Hanrahan, T., Mowat, N. A., Brunt, P. W., Sinclair, T. S., Ewen, S., Heys, S. D., and Eremin, O. (1998) Distal procto-colitis, natural cytotoxicity, and essential fatty acids. Am. J. Gastroenterol. 93, 804-809
32. Bosco, N., Brahmbhatt, V., Oliveira, M., Martin, F. P., Lichti, P., Raymond, F., Mansourian, R., Metairon, S., Pace-Asciak, C., Bastic Schmid, V., Rezzi, S., Haller, D., and Benyacoub, J. (2013) Effects of increase in fish oil intake on intestinal eicosanoids and inflammation in a mouse model of colitis. Lipids Health Dis. 12, 81
33. Middleton, S. J., Naylor, S., Woolner, J., and Hunter, J. O. (2002) A doubleblind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis. Aliment. Pharmacol. Ther. 16, 1131-1135
34. Woodworth, H. L., McCaskey, S. J., Duriancik, D. M., Clinthorne, J. F., Langohr, I. M., Gardner, E. M., and Fenton, J. I. (2010) Dietary fish oil alters T lymphocyte cell populations and exacerbates disease in a mouse model of inflammatory colitis. Cancer Res. 70, 7960-7969
35. Sikiric, P. (2014) From gut inflammation to gastrointestinal disorders current update on pathophysiology, molecular mechanism and pharmacological treatment modalities. Curr. Pharm. Des. 20, 1039-1040
36. Wallace, K. L., Zheng, L. B., Kanazawa, Y., and Shih, D. Q. (2014) Immunopathology of inflammatory bowel disease. World J. Gastroenterol. 20, 6-21
37. Simpson, S. J., Holländer, G. A., Mizoguchi, E., Allen, D., Bhan, A. K., Wang, B., and Terhorst, C. (1997) Expression of pro-inflammatory cytokines by TCR α β and TCR γ δ+ T cells in an experimental model of colitis. Eur. J. Immunol. 27, 17-25
38. Takedatsu, H., Michelsen, K. S., Wei, B., Landers, C. J., Thomas, L. S., Dhall, D., Braun, J., and Targan, S. R. (2008) TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology 135, 552-567
39. Rovedatti, L., Kudo, T., Biancheri, P., Sarra, M., Knowles, C. H., Rampton, D. S., Corazza, G. R., Monteleone, G., Di Sabatino, A., and Macdonald, T. T. (2009) Differential regulation of interleukin 17 and interferon γ production in inflammatory bowel disease. Gut 58, 1629-1636
40. Geremia, A., and Jewell, D. P. (2012) The IL-23/IL-17 pathway in inflammatory bowel disease. Expert Rev. Gastroenterol. Hepatol. 6, 223-237
41. Feng, T., Qin, H., Wang, L., Benveniste, E. N., Elson, C. O., and Cong, Y. (2011) Th17 cells induce colitis and promote Th1 cell responses through IL-17 induction of innate IL-12 and IL-23 production. J. Immunol. 186, 6313-6318
42. Müller, C. A., Autenrieth, I. B., and Peschel, A. (2005) Innate defenses of the intestinal epithelial barrier. Cell. Mol. Life Sci. 62, 1297-1307
43. Ouellette, A. J. (2011) Paneth cell α-defensins in enteric innate immunity. Cell. Mol. Life Sci. 68, 2215-2229
44. Paterson, J. C., and Watson, S. H. (1961) Paneth cell metaplasia in ulcerative colitis. Am. J. Pathol. 38, 243-249
45. Franke, A., Balschun, T., Karlsen, T. H., Sventoraityte, J., Nikolaus, S., Mayr, G., Domingues, F. S., Albrecht, M., Nothnagel, M., Ellinghaus, D., Sina, C., Onnie, C. M., Weersma, R. K., Stokkers, P. C., Wijmenga, C., et al. (2008) Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat. Genet. 40, 1319-1323
46. Julià, A., Domènech, E., Chaparro, M., García-Sánchez, V., Gomollón, F., Panés, J., Mañosa, M., Barreiro-De Acosta, M., Gutiérrez, A., Garcia-Planella, E., Aguas, M., Muñoz, F., Esteve, M., Mendoza, J. L., Vera, M., et al. (2014) A genome-wide association study identifies a novel locus at 6q22.1 associated with ulcerative colitis. Hum. Mol. Genet. 23, 6927-6934
47. Maxwell, J. R., Brown, W. A., Smith, C. L., Byrne, F. R., and Viney, J. L. (2009) Methods of inducing inflammatory bowel disease in mice. Curr. Protoc. Pharmacol. Chapter 5, Unit 5 58
48. Bressenot, A., Salleron, J., Bastien, C., Danese, S., Boulagnon-Rombi, C., and Peyrin-Biroulet, L. (2015) Comparing histological activity indexes in UC. Gut 64, 1412-1418
49. Moraes-Vieira, P. M., Yore, M. M., Dwyer, P. M., Syed, I., Aryal, P., and Kahn, B. B. (2014) RBP4 activates antigen-presenting cells, leading to adipose tissue inflammation and systemic insulin resistance. Cell Metab. 19, 512-526
50. Moraes-Vieira, P. M., Larocca, R. A., Bassi, E. J., Peron, J. P., Andrade-Oliveira, V., Wasinski, F., Araujo, R., Thornley, T., Quintana, F. J., Basso, A. S., Strom, T. B., and Câmara, N. O. (2014) Leptin deficiency impairs maturation of dendritic cells and enhances induction of regulatory T and Th17 cells. Eur. J. Immunol. 44, 794-806